XML 45 R30.htm IDEA: XBRL DOCUMENT
v3.25.1

INTANGIBLE ASSETS (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Intangible Assets Disclosure [Abstract] |
Summary of Finite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | March 31, 2025 |  | December 31, 2024
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset – sofosbuvir |  | $ | 10,720 |  |  | $ | (7,923) |  |  | $ | — |  |  | $ | 2,797 |  |  | $ | 10,720 |  |  | $ | (7,749) |  |  | $ | — |  |  | $ | 2,971 |
Intangible asset – axicabtagene ciloleucel |  | 7,110 |  |  | (2,822) |  |  | — |  |  | 4,288 |  |  | 7,110 |  |  | (2,721) |  |  | — |  |  | 4,389 |
Intangible asset – Trodelvy |  | 11,730 |  |  | (3,353) |  |  | — |  |  | 8,377 |  |  | 11,730 |  |  | (3,083) |  |  | — |  |  | 8,647 |
Intangible asset – Hepcludex |  | 845 |  |  | (351) |  |  | — |  |  | 494 |  |  | 845 |  |  | (329) |  |  | — |  |  | 516 |
Other |  | 1,479 |  |  | (971) |  |  | 1 |  |  | 510 |  |  | 1,474 |  |  | (940) |  |  | 1 |  |  | 535 |
Total finite-lived assets |  | 31,884 |  |  | (15,421) |  |  | 1 |  |  | 16,465 |  |  | 31,879 |  |  | (14,822) |  |  | 1 |  |  | 17,058 |
Indefinite-lived assets – IPR&D(1) |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |  |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |
Total intangible assets |  | $ | 34,774 |  |  | $ | (15,421) |  |  | $ | 1 |  |  | $ | 19,355 |  |  | $ | 34,769 |  |  | $ | (14,822) |  |  | $ | 1 |  |  | $ | 19,948 |
_______________________________ (1) The Indefinite-lived assets – IPR&D balance as of March 31, 2025 was comprised of $1.8 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide.
Summary of Indefinite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | March 31, 2025 |  | December 31, 2024
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset – sofosbuvir |  | $ | 10,720 |  |  | $ | (7,923) |  |  | $ | — |  |  | $ | 2,797 |  |  | $ | 10,720 |  |  | $ | (7,749) |  |  | $ | — |  |  | $ | 2,971 |
Intangible asset – axicabtagene ciloleucel |  | 7,110 |  |  | (2,822) |  |  | — |  |  | 4,288 |  |  | 7,110 |  |  | (2,721) |  |  | — |  |  | 4,389 |
Intangible asset – Trodelvy |  | 11,730 |  |  | (3,353) |  |  | — |  |  | 8,377 |  |  | 11,730 |  |  | (3,083) |  |  | — |  |  | 8,647 |
Intangible asset – Hepcludex |  | 845 |  |  | (351) |  |  | — |  |  | 494 |  |  | 845 |  |  | (329) |  |  | — |  |  | 516 |
Other |  | 1,479 |  |  | (971) |  |  | 1 |  |  | 510 |  |  | 1,474 |  |  | (940) |  |  | 1 |  |  | 535 |
Total finite-lived assets |  | 31,884 |  |  | (15,421) |  |  | 1 |  |  | 16,465 |  |  | 31,879 |  |  | (14,822) |  |  | 1 |  |  | 17,058 |
Indefinite-lived assets – IPR&D(1) |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |  |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |
Total intangible assets |  | $ | 34,774 |  |  | $ | (15,421) |  |  | $ | 1 |  |  | $ | 19,355 |  |  | $ | 34,769 |  |  | $ | (14,822) |  |  | $ | 1 |  |  | $ | 19,948 |
_______________________________ (1) The Indefinite-lived assets – IPR&D balance as of March 31, 2025 was comprised of $1.8 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide.

X
- Definition Intangible Assets Disclosure + References No definition available. + Details
Name: | gild_IntangibleAssetsDisclosureAbstract
Namespace Prefix: | gild_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration